Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms

Integrins Form an Expanding Diffusional Barrier that Coordinates Phagocytosis

(2016) Spencer A. Freeman et al.   CELL

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

(2015) T. R. W. Tipton et al.   BLOOD

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

(2014) Nuray Gül et al.   JOURNAL OF CLINICAL INVESTIGATION

Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving

(2014) P. V. Beum et al.   JOURNAL OF IMMUNOLOGY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Antibody-Based Immunotherapy of Cancer

(2012) Louis M. Weiner et al.   CELL

Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies

(2012) S. Derer et al.   JOURNAL OF IMMUNOLOGY

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

One target, different effects: a comparison of distinct therapeutic antibodies against the same targets

(2011) Hyunbo Shim   EXPERIMENTAL AND MOLECULAR MEDICINE

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

A general process for the development of peptide-based immunoassays for monoclonal antibodies

(2010) Ana B. Sanchez et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees

(2009) B. Varghese et al.   BLOOD

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Paths reunited: Initiation of the classical and lectin pathways of complement activation

(2009) Russell Wallis et al.   IMMUNOBIOLOGY

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily

(2009) Eun-Young Won et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Association of Fc RIIa (CD32a) with Lipid Rafts Regulates Ligand Binding Activity

(2009) S. Bournazos et al.   JOURNAL OF IMMUNOLOGY

Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand

(2009) A. Wyzgol et al.   JOURNAL OF IMMUNOLOGY

A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

(2008) Arturo Molina   Annual Review of Medicine

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   LEUKEMIA RESEARCH